Ann: Cohort 3 Pharmacokinetics in MND Patients Completed, page-79

Agreed @beazle,

I'd love to see a major institution (or two or three) aim to take a 5% - 10% shareholding and hoover up all available shares by doing so.

Hopefully we are on the radar of a few big investment players. The question is - what is the tipping point for them to press the Go button?

I don't think interim results will cut it unless Cohort 1 and 2 show incontrovertible evidence of efficacy. We may have to hang on until the full results for the entire study are available and conclusive. A willingness by Fight MND to fund a Phase 2 study and Orphan Drug Designation would have many interested parties starting to think that this MPL thingy is the real deal.

And with a Principal Investigator waiting in the US to commence the Phase 2 Human Cancer trial based on the Phase 1 MND results, we are poised to turn the corner.

Some on this forum are comparing PAA to RAC who managed to jump from cents to dollars in a hurry. I suspect we are destined to to do the same or even better if all the pieces fall into place over the next few months.

Cheers, Thrifty